Who is the manufacturer of afatinib (Gitaris)? Is the quality of medicines guaranteed?

Afatinib is produced by Bayer AG in Germany under the trade name Gilotrif. Bayer is a leading global pharmaceutical and life sciences company founded more than 150 years ago, dedicated to developing and producing high-quality medicines. As one of the anti-cancer drugs produced by Bayer, Gyterinib (afatinib) has been approved by many countries and regions around the world for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) and other types of cancer.

Bayer enjoys a high reputation in the pharmaceutical field, and the quality control and production processes of its products strictly follow international standards. As a targeted drug targeting EGFR mutations, Giteri's clinical data show that it has significant efficacy in the treatment of EGFR-mutated non-small cell lung cancer, and during the treatment process, patient safety and drug quality are highly guaranteed.

The production process of afatinib is carried out in strict accordance with Good Manufacturing Practices (GMP) to ensure that every tablet meets quality requirements. Bayer also conducts regular pharmaceutical quality inspections to ensure that drugs meet standards in terms of stability, purity and dosage consistency. In addition, Bayer has invested a lot of resources in drug research and development and clinical trials to ensure the efficacy and safety of afatinib.

For patients, when choosing Gyterinib (afatinib) as a treatment option, they can trust the quality assurance of the drug from Bayer. Moreover, Bayer also provides comprehensive after-sales service and patient support globally to ensure that patients receive timely and effective help during the treatment process. Therefore, patients can fully rely on the quality of the drug and the technical guarantee of the manufacturer when using afatinib.

Reference materials:https://www.giotrif.com/